Department of Vascular Surgery, Xuanwu Hospital, Capital Medical University and Institute of Vascular Surgery, Capital Medical University , Beijing , China.
Department of Surgery, Yale School of Medicine , New Haven, Connecticut.
Am J Physiol Cell Physiol. 2018 Dec 1;315(6):C885-C896. doi: 10.1152/ajpcell.00120.2018. Epub 2018 Nov 7.
We have previously shown that bone marrow-derived mesenchymal stem cells (BMSC) accelerate wound healing in a diabetic mouse model. In this study, we hypothesized that adipose tissue-derived stem cells (ADSC), cells of greater translational potential to human therapy, improve diabetic wound healing to a similar extent as BMSC. In vitro, the characterization and function of murine ADSC and BMSC as well as human diabetic and nondiabetic ADSC were evaluated by flow cytometry, cell viability, and VEGF expression. In vivo, biomimetic collagen scaffolds containing murine ADSC or BMSC were used to treat splinted full-thickness excisional back wounds on diabetic C57BL/6 mice, and human healthy and diabetic ADSC were used to treat back wounds on nude mice. Wound healing was evaluated by wound area, local VEGF-A expression, and count of CD31-positive cells. Delivery of murine ADSC or BMSC accelerated wound healing in diabetic mice to a similar extent, compared with acellular controls ( P < 0.0001). Histological analysis showed similarly increased cellular proliferation ( P < 0.0001), VEGF-A expression ( P = 0.0002), endothelial cell density ( P < 0.0001), numbers of macrophages ( P < 0.0001), and smooth muscle cells ( P < 0.0001) with ADSC and BMSC treatment, compared with controls. Cell survival and migration of ADSC and BMSC within the scaffolds were similar ( P = 0.781). Notch signaling was upregulated to a similar degree by both ADSC and BMSC. Diabetic and nondiabetic human ADSC expressed similar levels of VEGF-A ( P = 0.836) in vitro, as well as in scaffolds ( P = 1.000). Delivery of human diabetic and nondiabetic ADSC enhanced wound healing to a similar extent in a nude mouse wound model. Murine ADSC and BMSC delivered in a biomimetic-collagen scaffold are equivalent at enhancing diabetic wound healing. Human diabetic ADSC are not inferior to nondiabetic ADSC at accelerating wound healing in a nude mouse model. This data suggests that ADSC are a reasonable choice to evaluate for translational therapy in the treatment of human diabetic wounds.
我们之前已经证明骨髓间充质干细胞(BMSC)可加速糖尿病小鼠模型中的伤口愈合。在这项研究中,我们假设脂肪组织来源的干细胞(ADSC),更具有转化为人类治疗的潜力,能在类似程度上改善糖尿病伤口愈合。在体外,通过流式细胞术、细胞活力和 VEGF 表达来评估鼠 ADSC 和 BMSC 以及人糖尿病和非糖尿病 ADSC 的特征和功能。在体内,使用含有鼠 ADSC 或 BMSC 的仿生胶原支架来治疗糖尿病 C57BL/6 小鼠的夹板全层切除背部伤口,并使用人健康和糖尿病 ADSC 来治疗裸鼠的背部伤口。通过伤口面积、局部 VEGF-A 表达和 CD31 阳性细胞计数来评估伤口愈合。与无细胞对照相比,递送鼠 ADSC 或 BMSC 可在类似程度上加速糖尿病小鼠的伤口愈合(P<0.0001)。组织学分析显示,细胞增殖(P<0.0001)、VEGF-A 表达(P=0.0002)、内皮细胞密度(P<0.0001)、巨噬细胞数量(P<0.0001)和平滑肌细胞(P<0.0001)均有类似程度的增加,与对照组相比,ADSC 和 BMSC 治疗。ADSC 和 BMSC 在支架内的细胞存活和迁移相似(P=0.781)。ADSC 和 BMSC 均可上调类似程度的 Notch 信号。在体外和支架中,糖尿病和非糖尿病人 ADSC 表达相似水平的 VEGF-A(P=0.836)(P=1.000)。在裸鼠伤口模型中,递送人糖尿病和非糖尿病 ADSC 可在类似程度上增强伤口愈合。在仿生胶原支架中递送鼠 ADSC 和 BMSC 可等效增强糖尿病伤口愈合。在裸鼠模型中,人糖尿病 ADSC 在加速伤口愈合方面并不逊于非糖尿病 ADSC。这些数据表明,ADSC 是评估治疗人类糖尿病伤口的转化治疗的合理选择。